Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - NACDS, NCPA Praise Senate Action to Reduce Patient Drug Costs - February 15, 2019

Pharmacy News Article

 2/6/19 - NACDS, NCPA Praise Senate Action to Reduce Patient Drug Costs

ARLINGTON, Virginia, Feb. 5 The National Association of Chain Drug Stores issued the following news release:

The National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) today praised a bipartisan Senate letter to Health and Human Services Secretary Alex Azar. The letter thanked the Secretary for concepts in the Centers for Medicare & Medicaid Services' (CMS) proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, that would reduce patients' out-of-pocket drug costs through reform of pharmacy direct and indirect remuneration (DIR) fees in the Medicare Part D program.

Led by Sens. Shelley Moore Capito (R-WV) and Jon Tester (D-MT), and signed by 29 Senators, the letter states: "We believe the policy outlined in the proposed rule would provide needed relief from the impact pharmacy DIR fees have had on patients' out-of-pocket costs and community pharmacies."

The Senators point to the staggering increase in pharmacy DIR fees on pharmacies participating in the Part D program, which have increased by "more than 45,000 percent between 2010 and 2017." The Senators explain that these retroactive fees, which are taken back from pharmacies months later rather than at the point of sale, cause a reimbursement uncertainty that jeopardizes pharmacies. Loopholes in the method of calculating patients' copayments are such that the fees inflate the patients' financial responsibility as well.

"We are grateful to Sens. Capito and Testerand all the Senators who signed the letterfor highlighting the serious repercussions to patients and pharmacies that pharmacy DIR fees cause, and for urging Secretary Azar to finalize this reform quickly to help reduce patients' out-of-pocket costs, improve patient health outcomes, and reduce overall costs," said NACDS President & CEO Steven C. Anderson, IOM, CAE.

"We appreciate the Senators' support on this vital issue, which urgently needs to be resolved. The increase in pharmacy DIR fees has caused higher costs for patients, which lead to reduced medication adherence and poorer patient health outcomes," said NCPA CEO B. Douglas Hoey, pharmacist, MBA. "As CMS has noted, revising the structure of these fees could result in billions of dollars in savings for patients."

The Senators conclude by urging Secretary Azar to act swiftly on pharmacy DIR reform to eliminate the retroactive nature of these fees and to pass the subsequent savings on to those who need it mostpatients.

© 2019 Targeted News Service

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement